Oncostatin M and its role in fibrosis

Mechanisms of fibrosis: therapeutic translation for fibrotic disease

Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541 · see citing works

The pathogenesis of cardiac fibrosis

Kong, P., Christia, P., & Frangogiannis, N. G. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1349-6 · Cited by 1,572 · see citing works

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266 · see citing works

Choice of STATs and Other Substrates Specified by Modular Tyrosine-Based Motifs in Cytokine Receptors

Stahl, N., Farruggella, T. J., Boulton, T. G., Zhong, Z., Darnell, J. E., & Yancopoulos, G. D. (1995) · Science · doi:10.1126/science.7871433 · Cited by 979 · see citing works

Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease

Oxford IBD Cohort Investigators, West, N. R., Hegazy, A. N., Owens, B. M. J., Bullers, S. J., Linggi, B. E., Buonocore, S. M., Coccia, M., Görtz, D., This, S., et al. (2017) · Nature Medicine · doi:10.1038/nm.4307 · Cited by 814 · see citing works

Interleukin-6 Family CytokinesPreprint

Rose‐John, S. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028415 · Cited by 801 · see citing works

The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours

Thomas, S. J., Snowden, J. A., Zeidler, M. P., & Danson, S. J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.233 · Cited by 639 · see citing works

Angiopoietins: a link between angiogenesis and inflammation

Fiedler, U., & Augustin, H. G. (2006) · Trends in Immunology · doi:10.1016/j.it.2006.10.004 · Cited by 606 · see citing works

Idiopathic pulmonary fibrosis: pathogenesis and management

Sgalla, G., Iovene, B., Calvello, M., Ori, M., Varone, F., & Richeldi, L. (2018) · Respiratory Research · doi:10.1186/s12931-018-0730-2 · Cited by 573 · see citing works

Angiotensin II and Renal Fibrosis

Mezzano, S. A., Ruiz‐Ortega, M., & Egido, J. (2001) · Hypertension · doi:10.1161/hy09t1.094234 · Cited by 525 · see citing works

Oxidative stress and endothelial dysfunction in hypertension

Schulz, E., Gori, T., & Münzel, T. F. (2011) · Hypertension Research · doi:10.1038/hr.2011.39 · Cited by 503 · see citing works

Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells.

Zarling, J. M., SHOYAB, M., Marquardt, H., Hanson, M., Lioubin, M. N., & Todaro, G. J. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.24.9739 · Cited by 435 · see citing works

Interleukin-6: from an inflammatory marker to a target for inflammatory diseases

Rincón, M. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.07.003 · Cited by 328 · see citing works

Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities

Varga, J., Trojanowska, M. E., & Kuwana, M. (2017) · Journal of Scleroderma and Related Disorders · doi:10.5301/jsrd.5000249 · Cited by 323 · see citing works

Fibrosis—a lethal component of systemic sclerosis

Ho, Y. Y., Lagares, D., Tager, A. M., & Kapoor, M. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.53 · Cited by 307 · see citing works

SOCS3 binds specific receptor–JAK complexes to control cytokine signaling by direct kinase inhibition

Kershaw, N. J., Murphy, J. M., Liau, N. P. D., Varghese, L. N., Laktyushin, A., Whitlock, E. L., Lucet, I. S., Nicola, N. A., & Babon, J. J. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2519 · Cited by 301 · see citing works

Structures and biological functions of IL-31 and IL-31 receptors

Zhang, Q., Putheti, P., Zhou, Q., Liu, Q., & Gao, W. (2008) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2008.08.003 · Cited by 286 · see citing works

Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation

Ibrahim, S. H., Hirsova, P., & Gores, G. J. (2018) · Gut · doi:10.1136/gutjnl-2017-315691 · Cited by 278 · see citing works

Endothelial to Mesenchymal Transition (EndoMT) in the Pathogenesis of Human Fibrotic Diseases

Piera-Velázquez, S., Mendoza, F. A., & Jiménez, S. A. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5040045 · Cited by 276 · see citing works

Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)

Khanna, D., Denton, C. P., Lin, C. J. F., van Laar, J. M., Frech, T. M., Anderson, M. E., Baron, M., Chung, L., Fierlbeck, G., Lakshminarayanan, S., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211682 · Cited by 265 · see citing works

Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology

Hermanns, H. M. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.07.006 · Cited by 263 · see citing works

The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis.

Okamoto, H., Yamamura, M., Morita, Y., Harada, S., Makino, H., & Ota, Z. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400614 · Cited by 257 · see citing works

Serum YKL-40 is increased in patients with hepatic fibrosis

Johansen, J. S., Christoffersen, P., Møller, S., et al. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80095-1 · Cited by 252 · see citing works

Targeting Interleukin-6: All the Way to Treat Autoimmune and Inflammatory Diseases

Tanaka, T., & Kishimoto, T. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4666 · Cited by 245 · see citing works

Emerging role of interleukin‐31 and interleukin‐31 receptor in pruritus in atopic dermatitis

Furue, M., Yamamura, K., Kido‐Nakahara, M., Nakahara, T., & Fukui, Y. (2018) · Allergy · doi:10.1111/all.13239 · Cited by 240 · see citing works

A NEW BIOCHEMICAL MARKER FOR JOINT INJURY. ANALYSIS OF YKL-40 IN SERUM AND SYNOVIAL FLUID

Johansen, J. S., JENSEN, H. S., & Price, P. A. (1993) · Lara D. Veeken · doi:10.1093/rheumatology/32.11.949 · Cited by 230 · see citing works

JAK/STAT Pathways in Cytokine Signaling and Myeloproliferative Disorders: Approaches for Targeted Therapies

Jatiani, S., Baker, S. J., Silverman, L. R., & Reddy, E. P. (2010) · Genes & Cancer · doi:10.1177/1947601910397187 · Cited by 228 · see citing works

Interleukin 4 or oncostatin M induces a prolonged increase in P-selectin mRNA and protein in human endothelial cells.

Yao, L., Pan, J., Setiadi, H., Patel, K. D., & McEver, R. P. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.1.81 · Cited by 227 · see citing works

Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis

Zhang, H., Watanabe, R., Berry, G. J., Tian, L., Goronzy, J. J., & Weyand, C. M. (2017) · Circulation · doi:10.1161/circulationaha.117.030423 · Cited by 218 · see citing works

Cellular and molecular aspects of vascular dysfunction in systemic sclerosis

Trojanowska, M. E. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.102 · Cited by 216 · see citing works

The Enigmatic Cytokine Oncostatin M and Roles in Disease

Richards, C. D. (2013) · ISRN Inflammation · doi:10.1155/2013/512103 · Cited by 204 · see citing works

Differential Activation of Acute Phase Response Factor/Stat3 and Stat1 via the Cytoplasmic Domain of the Interleukin 6 Signal Transducer gp130

Hemmann, U., Gerhartz, C., Heesel, B., Sasse, J., Kurapkat, G., Grötzinger, J., Wollmer, A., Zhong, Z., Darnell, J., Graeve, L., et al. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.12999 · Cited by 197 · see citing works

Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors

Welsch, K., Holstein, J., Laurence, A. D. J., & Ghoreschi, K. (2017) · European Journal of Immunology · doi:10.1002/eji.201646680 · Cited by 170 · see citing works

Liver Fibrogenesis: A New Role for the Renin–Angiotensin System

Bataller, R. A., Sancho‐Bru, P., Ginès, P., & Brenner, D. A. (2005) · Antioxidants and Redox Signaling · doi:10.1089/ars.2005.7.1346 · Cited by 154 · see citing works

Mechanisms of Oncostatin M-Induced Pulmonary Inflammation and Fibrosis

Mozaffarian, A., Brewer, A. W., Trueblood, E. S., Luzina, I. G., Todd, N. W., Atamas, S. P., & Arnett, H. A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.7243 · Cited by 153 · see citing works

Oncostatin M and Leukemia Inhibitory Factor Do Not Use the Same Functional Receptor in Mice

Ichihara, M., Hara, T., Kim, H. J., Murate, T., & Miyajima, A. (1997) · Blood · doi:10.1182/blood.v90.1.165 · Cited by 152 · see citing works

Selective regulation of metalloproteinase inhibitor (TIMP-1) by oncostatin M in fibroblasts in culture

Richards, C. D., SHOYAB, M., Brown, T. J., & Gauldie, J. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.12.5596 · Cited by 146 · see citing works

Wall Stiffness Suppresses Akt/eNOS and Cytoprotection in Pulse-Perfused Endothelium

Peng, X., Haldar, S. M., Deshpande, S., Irani, K., & Kass, D. A. (2003) · Hypertension · doi:10.1161/01.hyp.0000049624.99844.3d · Cited by 144 · see citing works

Oncostatin M Stimulates Transcription of the Human α2(I) Collagen Gene via the Sp1/Sp3-binding Site

Ihn, H., LeRoy, E. C., & Trojanowska, M. E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.39.24666 · Cited by 141 · see citing works

Oncostatin M Induces Angiogenesis In Vitro and In Vivo

Vasse, M., Pourtau, J., Trochon-Joseph, V., Muraine, M., Vannier, J., Lu, H., Soria, J., & Soria, C. (1999) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.19.8.1835 · Cited by 137 · see citing works

High serum YKL‐40 level after surgery for colorectal carcinoma is related to short survival

Cintin, C., Johansen, J. S., Christensen, I. J., et al. (2002) · Cancer · doi:10.1002/cncr.10644 · Cited by 137 · see citing works

Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling

Junk, D. J., Bryson, B. L., Smigiel, J. M., Parameswaran, N., Bartel, C. A., & Jackson, M. W. (2017) · Oncogene · doi:10.1038/onc.2017.33 · Cited by 133 · see citing works

Regulation of Inflammatory Responses by Oncostatin M

Wallace, P. M., MacMaster, J. F., Rouleau, K. A., Brown, T. J., Loy, J. K., Donaldson, K. L., & Wahl, A. F. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.9.5547 · Cited by 129 · see citing works

High Serum YKL-40 Levels in Patients with Primary Breast Cancer is Related to Short Recurrence Free Survival

Johansen, J. S., Christensen, I. J., Riisbro, R., et al. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1024431000710 · Cited by 125 · see citing works

Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors

Kawaguchi, Y., Takagi, K., Hara, M., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.11364 · Cited by 115 · see citing works

Murine Oncostatin M Stimulates Mouse Synovial Fibroblasts in Vitro and Induces Inflammation and Destruction in Mouse Joints in Vivo

Langdon, C. M., Kerr, C. L., Hassen, M., Hara, T., Arsenault, A. L., & Richards, C. D. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64634-2 · Cited by 113 · see citing works

Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patients

Luzina, I. G., Atamas, S. P., Wise, R. A., Wigley, F. M., Choi, J., Xiao, H. Q., & White, B. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11080 · Cited by 112 · see citing works

Cloning and Characterization of a Specific Receptor for Mouse Oncostatin M

Lindberg, R. A., Juan, T., Welcher, A. A., Sun, Y. S., Cupples, R. L., Guthrie, B. A., & Fletcher, F. A. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.6.3357 · Cited by 112 · see citing works

Oncostatin M causes liver fibrosis by regulating cooperation between hepatic stellate cells and macrophages in mice

Matsuda, M., Tsurusaki, S., Miyata, N., Saijou, E., Okochi, H., Miyajima, A., & Tanaka, M. (2017) · Hepatology · doi:10.1002/hep.29421 · Cited by 111 · see citing works

Stimulation of Transforming Growth Factor-β1-Induced Endothelial-To-Mesenchymal Transition and Tissue Fibrosis by Endothelin-1 (ET-1): A Novel Profibrotic Effect of ET-1

Wermuth, P. J., Li, Z., Mendoza, F. A., & Jiménez, S. A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161988 · Cited by 110 · see citing works

Serum Level of YKL-40 is Elevated in Patients with Streptococcus pneumoniae Bacteremia and is Associated with the Outcome of the Disease

Kronborg, G., Østergaard, C., Weis, N. M., et al. (2002) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540110080233 · Cited by 109 · see citing works

Overexpression of OSM and IL-6 impacts the polarization of pro-fibrotic macrophages and the development of bleomycin-induced lung fibrosis

Ayaub, E. A., Dubey, A., Imani, J., Botelho, F., Kolb, M., Richards, C., & Ask, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-13511-z · Cited by 109 · see citing works

Effects of Oncostatin M on Human Cerebral Endothelial Cells and Expression in Inflammatory Brain Lesions

Ruprecht, K., Kuhlmann, T., Seif, F., Hummel, V., Kruse, N., Brück, W., & Rieckmann, P. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.11.1087 · Cited by 102 · see citing works

Oncostatin M stimulates proliferation, induces collagen production and inhibits apoptosis of human lung fibroblasts

Scaffidi, A. K., Mutsaers, S. E., Moodley, Y. P., McAnulty, R. J., Laurent, G. J., Thompson, P. J., & Knight, D. A. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704769 · Cited by 101 · see citing works

Reconstitution of the Functional Mouse Oncostatin M (OSM) Receptor: Molecular Cloning of the Mouse OSM Receptor β Subunit

Tanaka, M., Hara, T., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., & Miyajima, A. (1999) · Blood · doi:10.1182/blood.v93.3.804 · Cited by 96 · see citing works

Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer

Smigiel, J. M., Parameswaran, N., & Jackson, M. W. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0337 · Cited by 94 · see citing works

Oncostatin M-Preconditioned Mesenchymal Stem Cells Alleviate Bleomycin-Induced Pulmonary Fibrosis Through Paracrine Effects of the Hepatocyte Growth Factor

Lan, Y., Theng, S.-M., Huang, T.-T., Choo, K., Chen, C., Kuo, H.-P., & Chong, K. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2016-0054 · Cited by 91 · see citing works

IL-31–IL-31R interactions negatively regulate type 2 inflammation in the lung

Perrigoue, J., Li, J., Zaph, C., Goldschmidt, M. H., Scott, P., de Sauvage, F. J., Pearce, E. J., Ghilardi, N., & Artis, D. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061791 · Cited by 89 · see citing works

Endothelial dysfunction in systemic sclerosis

Altorok, N., Wang, Y., & Kahaleh, B. (2014) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000112 · Cited by 87 · see citing works

High serum levels of YKL‐40 in patients with systemic sclerosis are associated with pulmonary involvement

Nordenbæk, C. M., Johansen, J. S., HALBERG, P., Wiik, A., Garbarsch, C., Ullman, S., Price, P. A., & Jacobsen, S. (2005) · Scandinavian Journal of Rheumatology · doi:10.1080/03009740510018598 · Cited by 87 · see citing works

Increased KGF Expression Promotes Fibroblast Activation in a Double Paracrine Manner Resulting in Cutaneous Fibrosis

Canady, J., Arndt, S., Karrer, S., & Bosserhoff, A. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.389 · Cited by 83 · see citing works

Endothelial Cells Recruit Macrophages and Contribute to a Fibrotic Milieu in Bleomycin Lung Injury

Leach, H., Chrobak, I., Han, R., & Trojanowska, M. E. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0152oc · Cited by 82 · see citing works

IL-31-Driven Skin Remodeling Involves Epidermal Cell Proliferation and Thickening That Lead to Impaired Skin-Barrier Function

Singh, B. B., Jegga, A. G., Shanmukhappa, K. S., Edukulla, R., Khurana, G. H., Medvedovic, M., Dillon, S. R., & Madala, S. K. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161877 · Cited by 81 · see citing works

The IL-31/IL-31 receptor axis: general features and role in tumor microenvironment

Ferretti, E., Corcione, A., & Pistoia, V. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.3mr0117-033r · Cited by 77 · see citing works

Oncostatin M-induced effects on EMT in human proximal tubular cells: differential role of ERK signaling

Pollack, V., Sárközi, R., Bánki, Z., et al. (2007) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00130.2007 · Cited by 72 · see citing works

Angiotensin II induces skin fibrosis: a novel mouse model of dermal fibrosis

Stawski, L., Han, R. X., Bujor, A. M., et al. (2012) · Arthritis Research & Therapy · doi:10.1186/ar4028 · Cited by 72 · see citing works

A Mouse Model of Airway Disease: Oncostatin M-Induced Pulmonary Eosinophilia, Goblet Cell Hyperplasia, and Airway Hyperresponsiveness Are STAT6 Dependent, and Interstitial Pulmonary Fibrosis Is STAT6 Independent

Fritz, D. K., Kerr, C., Fattouh, R., Llop-Guevara, A., Khan, W. I., Jordana, M., & Richards, C. D. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.0903476 · Cited by 69 · see citing works

Oncostatin M-enhanced vascular endothelial growth factor expression in human vascular smooth muscle cells involves PI3K-, p38 MAPK-, Erk1/2- and STAT1/STAT3-dependent pathways and is attenuated by interferon-γ

Demyanets, S., Kaun, C., Rychli, K., Pfaffenberger, S., Kastl, S., Hohensinner, P. J., Rega‐Kaun, G., Katsaros, K. M., Afonyushkin, T., Bochkov, V. N., et al. (2010) · Basic Research in Cardiology · doi:10.1007/s00395-010-0141-0 · Cited by 68 · see citing works

Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study

Takeuchi, T., Thorne, C., Karpouzas, G. A., Sheng, S., Xu, W., Rao, R., Fei, K., Hsu, B. L., & Tak, P. P. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211328 · Cited by 68 · see citing works

Oncostatin M in the anti-inflammatory response

Wahl, A. F., & Wallace, P. M. (2001) · Annals of the Rheumatic Diseases · doi:10.1136/ard.60.90003.iii75 · Cited by 66 · see citing works

Oncostatin M Stimulates Collagen and Glycosaminoglycan Production by Cultured Normal Dermal Fibroblasts: Insensitivity of Sclerodermal and Keloidal Fibroblasts

Duncan, M. R., Hasan, A., & Berman, B. (1995) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12613623 · Cited by 64 · see citing works

Therapeutic targeting of the oncostatin M receptor-β prevents inflammatory heart failure

Pöling, J., Gajawada, P., Richter, M., et al. (2013) · Basic Research in Cardiology · doi:10.1007/s00395-013-0396-3 · Cited by 64 · see citing works

Oncostatin M induces basic fibroblast growth factor expression in endothelial cells and promotes endothelial cell proliferation, migration and spindle morphology

Wijelath, E. S., Carlsen, B., Cole, T., Chen, J., Kothari, S., & Hammond, W. P. (1997) · Journal of Cell Science · doi:10.1242/jcs.110.7.871 · Cited by 63 · see citing works

Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis

Stifano, G., Sornasse, T., Rice, L. M., Na, L., Chen‐Harris, H., Khanna, D., Jahreis, A., Zhang, Y., Siegel, J., & Lafyatis, R. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40455 · Cited by 62 · see citing works

Oncostatin M and Leukemia Inhibitory Factor Do Not Use the Same Functional Receptor in Mice

Ichihara, M., Hara, T., Kim, H. J., et al. (1997) · Blood · doi:10.1182/blood.v90.1.165.165_165_173 · Cited by 61 · see citing works

Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti- oncostatin M monoclonal antibody in rheumatoid arthritis: results from phase II randomized, placebo-controlled trials

Choy, E., Bendit, M., McAleer, D., Liu, F., Feeney, M. B., Brett, S. J., Zamuner, S., Campanile, A. M., & Toso, J. F. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4312 · Cited by 60 · see citing works

Erratum: Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease

Oxford IBD Cohort Investigators, West, N. R., Hegazy, A. N., Owens, B. M. J., Bullers, S. J., Linggi, B. E., Buonocore, S. M., Coccia, M., Görtz, D., This, S., et al. (2017) · Nature Medicine · doi:10.1038/nm0617-788d · Cited by 59 · see citing works

Oncostatin M overexpression induces skin inflammation but is not required in the mouse model of imiquimod‐induced psoriasis‐like inflammation

Pohin, M., Guesdon, W., Mekouo, A. A. T., Rabeony, H., Pâris, I., Atanassov, H., Favot, L., Mcheik, J. N., Bernard, F., Richards, C. D., et al. (2016) · European Journal of Immunology · doi:10.1002/eji.201546216 · Cited by 58 · see citing works

Oncostatin M binds to extracellular matrix in a bioactive conformation: Implications for inflammation and metastasis

Ryan, R. E., Martin, B. T., Mellor, L. F., Jacob, R. B., Tawara, K., McDougal, O. M., Oxford, J. T., & Jorcyk, C. L. (2015) · Cytokine · doi:10.1016/j.cyto.2014.11.007 · Cited by 57 · see citing works

Oncostatin M: a cytokine upregulated in human cirrhosis, increases collagen production by human hepatic stellate cells

Levy, M. T., Trojanowska, M. E., & Reuben, A. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80066-5 · Cited by 57 · see citing works

Human mast cells release oncostatin M on contact with activated T cells: Possible biologic relevance

Salamon, P., Shoham, N. G., Puxeddu, I., et al. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.08.054 · Cited by 56 · see citing works

Overexpression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelial–mesenchymal transition and poor overall survival

Kucia-Tran, J., Tulkki, V., Smith, S. P., Scarpini, C. G., Hughes, K., Araujo, A. M., Yan, K. Y. M., Botthof, J. G., Pérez-Gómez, E., Quintanilla, M., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.199 · Cited by 51 · see citing works

A model of inflammatory arthritis highlights a role for oncostatin M in pro-inflammatory cytokine-induced bone destruction via RANK/RANKL

Hui, W., Cawston, T., Richards, C., & Rowan, A. (2004) · Arthritis Research & Therapy · doi:10.1186/ar1460 · Cited by 49 · see citing works

Oncostatin M overexpression induces matrix deposition, STAT3 activation, and SMAD1 Dysregulation in lungs of fibrosis-resistant BALB/c mice

Wong, S. C., Botelho, F. M., Rodrigues, R., & Richards, C. D. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2014.81 · Cited by 49 · see citing works

Cross-sectional evaluation of YKL-40 serum concentrations in patients with systemic sclerosis. Relationship with clinical and serological aspects of disease.

MONTAGNA, G. L., D’Angelo, S., & Valentini, G. (2003) · PubMed · Cited by 49 · see citing works

IL-27: a double agent in the IL-6 family

Jones, G. W., Hill, D. G., Figueras, A. C., & Jones, S. A. (2018) · Clinical & Experimental Immunology · doi:10.1111/cei.13116 · Cited by 48 · see citing works

Earliest Phase of Systemic Sclerosis Typified by Increased Levels of Inflammatory Proteins in the Serum

Cossu, M., van Bon, L., Preti, C., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40243 · Cited by 46 · see citing works

Oncostatin M Enhances CCL21 Expression by Microvascular Endothelial Cells and Increases the Efficiency of Dendritic Cell Trafficking to Lymph Nodes

Sugaya, M., Fang, L., Cardones, A. R., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.11.7665 · Cited by 44 · see citing works

The gp130 ligand oncostatin M regulates tissue inhibitor of metalloproteinases-1 through ERK1/2 and p38 in human adult cardiac myocytes and in human adult cardiac fibroblasts: A possible role for the gp130/gp130 ligand system in the modulation of extracellular matrix degradation in the human heart

WEISS, T., Kvakan, H., Kaun, C., et al. (2005) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2005.03.015 · Cited by 43 · see citing works

Oncostatin M Modulates Fibroblast Function via Signal Transducers and Activators of Transcription Proteins–3

Nagahama, K. Y., Togo, S., Holz, O., MAGNUSSEN, H., Liu, X., Seyama, K., Takahashi, K., & Rennard, S. I. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2012-0460oc · Cited by 42 · see citing works

Systems biology of IL-6, IL-12 family cytokines

Dittrich, A., Hessenkemper, W., & Schaper, F. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.07.002 · Cited by 41 · see citing works

Elevated TGF-β1/IL-31 Pathway Is Associated with the Disease Severity of Hepatitis B Virus–Related Liver Cirrhosis

Ming, D., Yu, X., Guo, R., et al. (2015) · Viral Immunology · doi:10.1089/vim.2014.0142 · Cited by 39 · see citing works

Oncostatin M Gene Therapy Attenuates Liver Damage Induced by Dimethylnitrosamine in Rats

Hamada, T., Sato, A., Hirano, T., Yamamoto, T., Son, G., Onodera, M., Torii, I., Nishigami, T., Tanaka, M., Miyajima, A., et al. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.060972 · Cited by 37 · see citing works

Oncostatin M is a novel inhibitor of TGF-β1-induced matricellular protein expression

Sárközi, R., Hauser, C., Noppert, S.-J., Kronbichler, A., Pirklbauer, M., Haller, V., Grillari, J., Grillari‐Voglauer, R., Mayer, G. J., & Schramek, H. (2011) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00123.2011 · Cited by 36 · see citing works

Oncostatin M-induced activation of stress-activated MAP kinases depends on tyrosine 861 in the OSM receptor and requires Jak1 but not Src kinases

Böing, I., Stroß, C., Radtke, S., Lippok, B. E., Heinrich, P. C., & Hermanns, H. M. (2005) · Cellular Signalling · doi:10.1016/j.cellsig.2005.03.015 · Cited by 35 · see citing works

Merkel cells in the human oesophagus

Harmse, J. L., Carey, F. A., Baird, A., Craig, S., Christie, K. N., Hopwood, D., & Lucocq, J. M. (1999) · Journal of Pathology · doi:10.1002/(sici)1096-9896(199910)189:2 · Cited by 33 · see citing works

Angiotensin II and Cardiac Fibrosis

Brecher, P. I. (1996) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(96)00072-2 · Cited by 32 · see citing works

Cyclooxygenase‐2 activity is necessary for the angiogenic properties of oncostatin M

Pourtau, J., Mirshahi, F., Li, H., et al. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01301-0 · Cited by 31 · see citing works

Oncostatin M-Induced IL-6 Expression in Murine Fibroblasts Requires the Activation of Protein Kinase Cδ

Smyth, D. C., Kerr, C. L., & Richards, C. D. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.12.8740 · Cited by 30 · see citing works

Negative regulation of onconstatin M signaling by suppressor of cytokine signaling (SOCS-3).

Magrangeas, F., Boisteau, O., DENIS, S., et al. (2001) · PubMed · Cited by 29 · see citing works

Oncostatin M inhibits TGF-β1-induced CTGF expression via STAT3 in human proximal tubular cells

Sárközi, R., Flucher, K., Haller, V., et al. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.07.042 · Cited by 23 · see citing works

Oncostatin M-induced cardiomyocyte dedifferentiation regulates the progression of diabetic cardiomyopathy through B-Raf/Mek/Erk signaling pathway

Zhang, X., Ma, S., Zhang, R., Li, S., Zhu, D., Han, D. H., Li, X., Li, C., Yan, W., Sun, D., et al. (2016) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv137 · Cited by 23 · see citing works

Cells from the skin of patients with systemic sclerosis secrete chitinase 3-like protein 1

Ho, Y. Y., Baron, M. G., Recklies, A. D., Roughley, P. J., & Mort, J. S. (2014) · BBA Clinical · doi:10.1016/j.bbacli.2013.12.001 · Cited by 22 · see citing works

Oncostatin M regulates osteogenic differentiation of murine adipose-derived mesenchymal progenitor cells through a PKCdelta-dependent mechanism

Smyth, D. C., Takenaka, S., Yeung, C., & Richards, C. D. (2015) · Cell and Tissue Research · doi:10.1007/s00441-014-2099-y · Cited by 20 · see citing works

Oncostatin M in the development of metabolic syndrome and its potential as a novel therapeutic target

Komori, T., & Morikawa, Y. (2017) · Anatomical Science International · doi:10.1007/s12565-017-0421-y · Cited by 19 · see citing works

Potential of Oncostatin M to accelerate diabetic wound healing

Shin, S. H., Han, S., Jeong, S., & Kim, W. (2012) · International Wound Journal · doi:10.1111/j.1742-481x.2012.01107.x · Cited by 17 · see citing works

Distinctive pro-inflammatory gene signatures induced in articular chondrocytes by oncostatin M and IL-6 are regulated by Suppressor of Cytokine Signaling-3

Liu, X., Liu, R., Croker, B. A., Lawlor, K. E., Smyth, G. K., & Wicks, I. P. (2015) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2015.05.011 · Cited by 17 · see citing works

Oncostatin M regulates endothelin-1 production in human endothelial cells

Saijonmaa, O. J., Nyman, T., Pacek, P., et al. (1998) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1998.275.2.h662 · Cited by 12 · see citing works

Oncostatin M is a FIP 1L1/ PDGFRA ‐dependent mediator of cytokine production in chronic eosinophilic leukemia

Hoermann, G., Cerny‐Reiterer, S., Sadovnik, I., Müllauer, L., Bilban, M., Gröger, M., Horny, H. ‐., Reiter, A., Schmitt-Graeff, A. H., Mannhalter, C., et al. (2013) · Allergy · doi:10.1111/all.12139 · Cited by 11 · see citing works

INDUCTION OF ANGIOTENSIN-CONVERTING ENZYME BY ONCOSTATIN M IN HUMAN ENDOTHELIAL CELLS

Saijonmaa, O. J., Nyman, T., Kosonen, R., et al. (2000) · Cytokine · doi:10.1006/cyto.2000.0703 · Cited by 11 · see citing works

Interleukin-6 and Related Proteins as Biomarkers in Systemic Sclerosis

Denton, C. P., & Ong, V. H. (2017) · Journal of Scleroderma and Related Disorders · doi:10.5301/jsrd.5000266 · Cited by 10 · see citing works

Microvascular Endothelial Cells Poised to Take Center Stage in Experimental Renal Fibrosis

Daehn, I. S., & Böttinger, E. P. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014121170 · Cited by 8 · see citing works

Negative regulation of oncostatin M (OM) signalling by suppressor of cytokine signalling-3 (SOCS-3).

Magrangeas, F., Boisteau, O., DENIS, S., et al. (2001) · European Cytokine Network · Cited by 5 · see citing works

Serum human cartilage glycoprotein-39 in patients with systemic sclerosis: relationship to skin and articular manifestation

Wcisło-Dziadecka, D. L., Kotulska, A. T., Brzezińska-Wcisło, L. A., et al. (2010) · Clinical Rheumatology · doi:10.1007/s10067-010-1462-y · Cited by 5 · see citing works

OP0048 IL-31 Is An Inflammatory Pro-Fibrotic Factor Elevated in A Subset of Scleroderma Patients with Severe Pruritus

Arumalla, N., Zafar, S., Rosario, H., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-eular.4916 · Cited by 5 · see citing works

THU0026 Osm is more effective than il-6 at inducing endomt of human dermal microvascular cells

Nevin, K., Stawski, L., Feeney, M. B., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-eular.1271 · Cited by 2 · see citing works

Oncostatin M Induces Barrier Dysfunction in Human Brain Microvascular Endothelium via Snail‐Dependent Repression of TAMPs

Wertz, T. S., Hoettels, B. A., Tawara, K., et al. (2017) · The FASEB Journal · doi:10.1096/fasebj.31.1_supplement.679.9 · Cited by 1 · see citing works

Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF)

Aribindi, K., Liu, G. Y., & Albertson, T. E. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2396121 · Cited by 17 · see citing works

PRL-Induced ER Gene Expression Is Mediated by Janus Kinase 2 (Jak2) While Signal Transducer and Activator of Transcription 5b (Stat5b) Phosphorylation Involves Jak2 and a Second Tyrosine Kinase

Frasor, J. (2001) · Molecular Endocrinology · doi:10.1210/me.15.11.1941 · Cited by 11 · see citing works

JAK2V617F Drives Mcl-1 Expression and Sensitizes Hematologic Cell Lines to Dual Inhibition of JAK2 and Bcl-xL

Guo, J. Q., Roberts, L., Chen, Z., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0114363 · Cited by 38 · see citing works

IL-15; B cell lymphoma 2 (BCL-2; BCL2); BCL-XL; janus kinase-3 (JAK-3); signal transducer and activator of transcription 5 (STAT5)

(2010) · Science-Business eXchange · doi:10.1038/scibx.2010.610

Novel Role of Janus Kinase 1 in the Regulation of Oncostatin M Receptor Surface Expression

Radtke, S., Hermanns, H. M., Haan, C., de Leur, H. S.-V., Heinrich, P. C., Behrmann, I., & Gascan, H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m100822200 · Cited by 87 · see citing works

JAK2-STAT3 signaling pathway plays a negative regulatory role in the healing process of mandibular defects in rats

Li, Z. B., & Li, D. Q. (2015) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2015.08.221